Biotest AG:Biotest obtained approval for improved Hepatect® product in six European countries
Biotest AG / Regulatory Approval
Corporate news transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Marketing of the preparation for hepatitis prophylaxis is planned for this
year. Modern manufacturing procedures will facilitate a higher degree of
product purity and optimum use of raw materials.
Dreieich, 2 November 2006. The immunglobulin Hepatect® manufactured by
Biotest using modern filter aid procedures, can now be marketed in six
European countries. The responsible authorities in Belgium, Germany, Italy,
the Netherlands, Austria, and Portugal granted approval for the new product
generation as part of an application for product variation. The first sales
of the new generation of preparation are scheduled to take place before the
end of the year. The preparation is primarily indicated for hepatitis
prophylaxis occurring in liver transplant patients or newborns.
The new Hepatect® replaces the previous product sold in the respective
markets. In light of a further increase in quality, Biotest anticipates
additional sales potential for the next few years. In addition, the company
will pursue product approval in other European markets.
With the filter aid procedure the individual protein components are
separated from the blood plasma with special filters, resulting in a better
utilisation of the raw material (blood plasma), as compared to centrifuge
production. With the new Hepatect® product and the polyvalent
immunoglobulin, Intratect®, Biotest’s key immunoglobulin products are now
manufactured using the filter aid procedure. Ensuring that its production
facilities are equipped with the latest technology is one of the core
elements of the Biotest strategy in the Pharmaceuticals division.
About Biotest
Biotest AG, Dreieich, Germany, is a company that researches and
manufactures pharmaceutical, biotherapeutic and diagnostic products and has
specialised in immunology and haematology. In its Pharmaceutical segment,
Biotest develops immunoglobulines, clotting factors and albumins based on
human blood plasma. These are used for diseases of the immune system or
haematopoietic system. In addition, Biotest also researches into the
clinical development of monoclonal antibodies, including in the indications
of rheumatoid arthritis and blood cancer. The Diagnostic segment spans
reagents and serology and microbiology systems which are used, for example,
in blood transfusions. Biotest has around 1,100 employees worldwide and its
shares are listed in the Frankfurt Stock Exchange's Prime Standard.
Biotest AG: Dr. Michael Ramroth, Tel. +49 6103 801-338
Fax: +49 6103 801-347, e-mail: michael.ramroth @biotest.de
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
WKN, ISIN ordinary share: 522720, DE0005227201
WKN, ISIN preference share: 522723, DE0005227235
Listed: Prime Standard/official trading
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
DGAP 02.11.2006
----------------------------------------------------------------------
Language: English
Issuer: Biotest AG
Landsteinerstr. 5
63303 Dreieich Deutschland
Phone: +49 - 6103 / 801 - 0
Fax: +49 - 6103 / 801 - 150
E-mail: mail@biotest.de
WWW: www.biotest.de
ISIN: DE0005227201, DE0005227235
WKN: 522720, 522723
Indices:
Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in
Berlin-Bremen, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
